TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20605441

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 10 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine 20 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 10 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 48
Study: 17921382

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU as retinyl palmitate)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Iodine supplementation (191 mg I as oral iodized oil)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Combination of iodine and vitamin A supplementation
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 15505638

Group type: EXPERIMENTAL
Intervention: Val/Met variant (rs4680)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: rs4633 variant
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Three-marker haplotype (rs737865-rs4680-rs165599)
Number of subjects: 107
Study: 12562409

Group type: EXPERIMENTAL
Intervention: SLIPA™
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway with open drainage tube
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard laryngeal mask airway
Number of subjects: 120

Group type: COMPARATOR
Intervention: SLIPA™ and standard laryngeal mask airway
Number of subjects: 120
Study: 10384900

Group type: EXPERIMENTAL
Intervention: Digital hearing aid (Senso)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Analogue hearing aid (Logo)
Number of subjects: 28
Study: 8696714

Group type: EXPERIMENTAL
Intervention: MIP regimen (mitomycin C 6 mg/m2 on day 1, ifosfamide 1500 mg/m2 on days 1-3, cisplatin 30 mg/m2 on days 1-3 every 4 weeks)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MIP regimen
Number of subjects: 72
Study: 1948213

Group type: EXPERIMENTAL
Intervention: Cephalexin (500 mg bid or qid)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ofloxacin (300 or 400 mg bid)
Number of subjects: 72
Study: 6657039

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30264137

Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy (dCBT)
Number of subjects: 1711
Study: 29528863

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 296

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 296
Study: 26545405

Group type: COMPARATOR
Intervention: BMI < 25
Number of subjects: 15538

Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide treatment
Number of subjects: 15538

Group type: EXPERIMENTAL
Intervention: ER-positive disease
Number of subjects: 15538
Study: 24694986

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Base-producing fruits and vegetables
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 108
Study: 22162050

Group type: EXPERIMENTAL
Intervention: Pre-hospital tirofiban
Number of subjects: 1398
Study: 20669815

Group type: EXPERIMENTAL
Intervention: 8% strontium acetate and 1040 ppm fluoride dentifrice (test dentifrice)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1450 ppm fluoride dentifrice (control dentifrice)
Number of subjects: 79
Study: 17643586

Group type: EXPERIMENTAL
Intervention: High-dose tirofiban
Number of subjects: 120

Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-dose tirofiban + clopidogrel 600-mg loading dose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Eptifibatide + clopidogrel 600-mg loading dose
Number of subjects: 120
Study: 16046365

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention (up to six 30-minute sessions focused on cardiac-related fears)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study: 12029281

Group type: EXPERIMENTAL
Intervention: Hypnorelaxation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Occlusal appliance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Minimal treatment
Number of subjects: 40
Study: 9809692

Group type: EXPERIMENTAL
Intervention: Alcohol restriction (maximum of 15 mL/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Constant drinking habits
Number of subjects: 34
Study: 7631286

Group type: EXPERIMENTAL
Intervention: Beta-blocking agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonist + beta-blocking agent
Number of subjects: 0
Study: 2575833

Group type: EXPERIMENTAL
Intervention: 0.8 mg pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.6 mg pindolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 675837

Group type: EXPERIMENTAL
Intervention: trichlorophone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: metronidazole
Number of subjects: 18

Group type: COMPARATOR
Intervention: metronidazole, tinidazole, mebendazole, trichlorophone, oxamniquine and pyrantel pamoate
Number of subjects: 18
Study: 30832198

Group type: EXPERIMENTAL
Intervention: Psychoanalysis (PA)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 169
Study: 28973024

Group type: EXPERIMENTAL
Intervention: Armeo-Power training with muscle vibration (group-A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Armeo-Power training without muscle vibration (group-B)
Number of subjects: 20
Study: 25633573

Group type: EXPERIMENTAL
Intervention: Paricalcitol 1 mcg administered orally once daily for three months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered orally once daily for three months
Number of subjects: 60
Study: 23046418

Group type: EXPERIMENTAL
Intervention: LOOSE (n = 15) - instructed to 'keep the ball away from the loose defender'
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: TTF (n = 15) - instructed to 'take the first option'
Number of subjects: 46

Group type: COMPARATOR
Intervention: NI (control) (n = 16) - given no instructions
Number of subjects: 46
Study: 22130240

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous bolus
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg intravenous bolus
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1.05 mg/kg intravenous bolus
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per hour infusion for 4 h
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 19585825

Group type: EXPERIMENTAL
Intervention: Long acting nifedipine (Nicardia retard 10/20/30 CD)
Number of subjects: 1632
Study: 16719648

Group type: EXPERIMENTAL
Intervention: Theory-based predictions of psychological experiments in the distant future
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictions of performance on near and distant future tests
Number of subjects: 0
Study: 15253685

Group type: EXPERIMENTAL
Intervention: IFNbeta-1b (Betaseron)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) IFNbeta-1a (Avonex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) IFNbeta-1a (Rebif)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFNbeta products
Number of subjects: 0
Study: 11693798

Group type: EXPERIMENTAL
Intervention: Cisplatin (30 mg/m2 daily for 3 days) + Vindesine (2.5 mg/m2 only day 1) + Dacarbazine (DTIC) (250 mg/m2 daily for 3 consecutive days) + Interferon-alpha (3 MIU i.m. 3x/wk continuously)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) (800 mg/m2 day 1) + Interferon-alpha (3 MIU i.m. 3x/wk continuously)
Number of subjects: 51
Study: 9350957

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HAD)
Number of subjects: 0
Study: 8204227

Group type: EXPERIMENTAL
Intervention: 0.8 mg/kg of i.v. ketorolac
Number of subjects: 50

Group type: COMPARATOR
Intervention: No additional analgesic (morphine only group)
Number of subjects: 50
Study: 3311438

Group type: EXPERIMENTAL
Intervention: One tablet of Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Two tablets of Fansimef
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Three tablets of Fansimef
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 31561648

Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency ablation (CRFA)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Geniculate local anesthetic block
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Repeated procedure (n = 43)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA; n = 21)
Number of subjects: 205
Study: 28140486

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 30
Study: 25762805

Group type: EXPERIMENTAL
Intervention: Prehospital hypothermia
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 508
Study: 23811853

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 15 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 29
Study: 21457428

Group type: EXPERIMENTAL
Intervention: Canagliflozin (10, 30, 100, 200, 400, 600 or 800 mg q.d. or 400 mg b.i.d.)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Canagliflozin (doses >200 mg before breakfast)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 17057562

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg + Ketorolac 60 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (C): IM chorpheniramine 20 mg + IV normal saline
Number of subjects: 80
Study: 15064540

Group type: EXPERIMENTAL
Intervention: Interval debulking surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by interval debulking surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second-look operation
Number of subjects: 0
Study: 11694377

Group type: EXPERIMENTAL
Intervention: Two-man FNAB technique
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard FNAB technique
Number of subjects: 44
Study: 9400786

Group type: EXPERIMENTAL
Intervention: MSL-109, 60 mg intravenously every 2 weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: MSL-109, 60 mg intravenously every 2 weeks (relapsed retinitis)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo (relapsed retinitis)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: MSL-109, 60 mg intravenously every 2 weeks (newly diagnosed retinitis)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo (newly diagnosed retinitis)
Number of subjects: 209
Study: 8265305

Group type: EXPERIMENTAL
Intervention: Oral administration of human serum immunoglobulin (300 mg/kg body weight)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 98
Study: 3687522

Group type: EXPERIMENTAL
Intervention: Real smoking
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 12
Study: 28255655

Group type: EXPERIMENTAL
Intervention: 2.5 mL of 1% HA (H-HA)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 0.8 mL of 1% HA (L-HA)
Number of subjects: 168

Group type: COMPARATOR
Intervention: 2.5 mL of 0.01% HA (control group)
Number of subjects: 168
Study: 27464313

Group type: EXPERIMENTAL
Intervention: Applied Relaxation Training (ART)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 201
Study: 24632760

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy for primary care (PST-PC)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Dietary coaching
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Both PST-PC and dietary coaching
Number of subjects: 247
Study: 22686556

Group type: EXPERIMENTAL
Intervention: Individual supervision
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group supervision
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control (no supervision)
Number of subjects: 42
Study: 20837300

Group type: EXPERIMENTAL
Intervention: Moderate whole body hypothermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care on normothermia
Number of subjects: 0
Study: 19083441

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (vitamin C 1000 mg and vitamin E 800 IU)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study: 11755291

Group type: EXPERIMENTAL
Intervention: Education and support intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 9881881

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (20 mg/d)
Number of subjects: 343

Group type: COMPARATOR
Intervention: No beta-carotene supplementation (Control)
Number of subjects: 343
Study: 8061849

Group type: EXPERIMENTAL
Intervention: Spirapril treatment (initial dose 6 or 12 mg once daily, titrated to 3-24 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spirapril treatment
Number of subjects: 11
Study: 2647122

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 4904222

Group type: EXPERIMENTAL
Intervention: Hyperosmolar and hypoosmolar solutions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duodenal ulcer patients
Number of subjects: 0
Study: 31158425

Group type: EXPERIMENTAL
Intervention: Social skills intervention (SSI) for 10 weeks
Number of subjects: 53
Study: 27856269

Group type: EXPERIMENTAL
Intervention: Maintain antimicrobials
Number of subjects: 176

Group type: COMPARATOR
Intervention: Withdraw antimicrobials
Number of subjects: 176
Study: 26132535

Group type: EXPERIMENTAL
Intervention: Veterans with children in the home
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Having children in the home
Number of subjects: 94
Study: 23048188

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 478

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 478
Study: 21321036

Group type: EXPERIMENTAL
Intervention: BW-GA-weight-gain model
Number of subjects: 367
Study: 19221377

Group type: EXPERIMENTAL
Intervention: High-frequency face-to-face lifestyle modification counseling (HF-F2F)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: High-frequency telephone counseling (HF-TEL)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Low-frequency face-to-face counseling (LF-F2F)
Number of subjects: 376

Group type: COMPARATOR
Intervention: High-frequency email counseling (HF-EMAIL)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Self-help (SELF)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 376
Study: 16500492

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced 3D dobutamine stress echocardiography
Number of subjects: 78

Group type: COMPARATOR
Intervention: Contrast-enhanced 2D dobutamine stress echocardiography
Number of subjects: 78
Study: 15555700

Group type: EXPERIMENTAL
Intervention: Short-term individual psychotherapy
Number of subjects: 60
Study: 11099758

Group type: EXPERIMENTAL
Intervention: 5 mg of dexamphetamine sulphate
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 10 mg of dexamphetamine sulphate
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 9313019

Group type: EXPERIMENTAL
Intervention: High social class
Number of subjects: 2145

Group type: COMPARATOR
Intervention: Low or middle social class
Number of subjects: 2145
Study: 7921303

Group type: EXPERIMENTAL
Intervention: Daily vitamin and mineral supplements for 6 years
Number of subjects: 3318

Group type: EXPERIMENTAL
Intervention: Daily supplementation of four different vitamin and mineral combinations for 5 1/4 years
Number of subjects: 3318

Group type: COMPARATOR
Intervention: Placebo for 6 years
Number of subjects: 3318

Group type: COMPARATOR
Intervention: Placebo for 5 1/4 years
Number of subjects: 3318
Study: 30928926

Group type: EXPERIMENTAL
Intervention: Group music therapy (GMT)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Recreational choir singing (RCS)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Combination of GMT and RCS
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: All interventions (GMT, RCS, both)
Number of subjects: 1000
Study: 29798206

Group type: EXPERIMENTAL
Intervention: Combined therapy with 10mg oral ebastine plus 200 μg intranasal mometasone furoate once daily (combined group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Double-dose oral ebastine 20 mg once daily (double-dose group)
Number of subjects: 82
Study: 27645761

Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 44
Study: 24462785

Group type: EXPERIMENTAL
Intervention: Juglans regia leaf extract (100mg, two times a day for 3 months)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (100mg, two times a day for 3 months)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Juglans regia leaf extract
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (Juglans regia and placebo)
Number of subjects: 61
Study: 22561772

Group type: EXPERIMENTAL
Intervention: Occlusion correction only (n=14)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Muscle Relaxant + anti‐depressant drug (n=26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Physiotherapy + antidepressant drug + muscle relaxant (n=6)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Appliance + muscle relaxant (n=4)
Number of subjects: 50
Study: 19667999

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of metformin 1700 mg/day and rosiglitazone 4 mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Metformin 1700 mg/day
Number of subjects: 64
Study: 18721168

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII), n = 34
Number of subjects: 72

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI), n = 38
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 17135985

Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine (FLX) and cognitive-behavioral therapy (CBT)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Clinical management with pill placebo (PBO)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Responders by CGI-I criteria
Number of subjects: 439
Study: 14575277

Group type: EXPERIMENTAL
Intervention: manidipine 20 mg daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: nifedipine 60 mg daily
Number of subjects: 101
Study: 11004652

Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for T(x) distance
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for vertebra(apex)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for Rz
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for CDA
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Interexaminer reliability among 3 examiners
Number of subjects: 3
Study: 8713789

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 x 10(6) U/m2)
Number of subjects: 8
Study: 1383574

Group type: EXPERIMENTAL
Intervention: finasteride (10 mg per day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 3996091

Group type: EXPERIMENTAL
Intervention: Tinidazole (500 mg intravenous infusion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral tinidazole
Number of subjects: 80
Study: 31291515

Group type: EXPERIMENTAL
Intervention: Galcanezumab (300 mg, subcutaneously at baseline and at 1 month)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (subcutaneously at baseline and at 1 month)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Galcanezumab (300 mg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 28702899

Group type: EXPERIMENTAL
Intervention: Complex antioxidant (antiOx)
Number of subjects: 63

Group type: COMPARATOR
Intervention: One-a-day multivitamin (mV)
Number of subjects: 63
Study: 27235953

Group type: EXPERIMENTAL
Intervention: Dance stimuli (various physical parameters)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Dance stimuli (motion energy, luminance)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Dance stimuli (roundedness in posture shape)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Dance stimuli (impressive movements)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Dance stimuli (imagery and autobiographical memories)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Dance stimuli (physical parameters)
Number of subjects: 97
Study: 24853120

Group type: EXPERIMENTAL
Intervention: Curcuminoids (1500 mg/day in 3 divided doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22038086

Group type: EXPERIMENTAL
Intervention: Manual-based psychological group program (10 sessions over 10 months)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 337
Study: 20350836

Group type: EXPERIMENTAL
Intervention: Real rTMS (1800 pulses; 1 Hz rate; intensity just below active motor threshold)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 9
Study: 17368094

Group type: COMPARATOR
Intervention: Memantine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6